{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:24:47Z","timestamp":1790112287288,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P3-0308"],"award-info":[{"award-number":["P3-0308"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11096-020-01008-1","type":"journal-article","created":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T12:02:51Z","timestamp":1584100971000},"page":"445-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Risk of major bleeding in elderly patients with atrial fibrillation on direct oral anticoagulants: real world experience"],"prefix":"10.1007","volume":"42","author":[{"given":"Petra","family":"\u0160inigoj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Vene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Ko\u0161melj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Mavri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,13]]},"reference":[{"issue":"8","key":"1008_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke. 1991;22(8):983\u20138.","journal-title":"Stroke"},{"issue":"11","key":"1008_CR2","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","volume":"44","author":"S Bj\u00f6rck","year":"2013","unstructured":"Bj\u00f6rck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited. Stroke. 2013;44(11):3103\u20138.","journal-title":"Stroke"},{"issue":"1","key":"1008_CR3","doi-asserted-by":"publisher","first-page":"e001486","DOI":"10.1161\/JAHA.114.001486","volume":"4","author":"M Haim","year":"2015","unstructured":"Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"1008_CR4","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1161\/STROKEAHA.109.558759","volume":"40","author":"G Saposnik","year":"2009","unstructured":"Saposnik G, Black SE, Hakim A, Fang J, Tu JV, Kapral MK. Age disparities in stroke quality of care and delivery of health services. Stroke. 2009;40(10):3328\u201335.","journal-title":"Stroke"},{"issue":"38","key":"1008_CR5","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893\u2013962.","journal-title":"Eur Heart J"},{"issue":"4","key":"1008_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/heartjnl-2016-309832","volume":"103","author":"AJ Camm","year":"2017","unstructured":"Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J-P, Berge E, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017;103(4):307\u201314.","journal-title":"Heart"},{"issue":"1","key":"1008_CR7","doi-asserted-by":"publisher","first-page":"31477","DOI":"10.1038\/srep31477","volume":"6","author":"L Staerk","year":"2016","unstructured":"Staerk L, Fosb\u00f8l EL, Gadsb\u00f8ll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, et al. Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011\u20132015 in Denmark. Sci Rep. 2016;6(1):31477.","journal-title":"Sci Rep"},{"issue":"21","key":"1008_CR8","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","volume":"123","author":"JW Eikelboom","year":"2011","unstructured":"Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation. 2011;123(21):2363\u201372.","journal-title":"Circulation"},{"issue":"2","key":"1008_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"JL Halperin","year":"2014","unstructured":"Halperin JL, Hankey GJ, Wojdyla DM, Piccini JP, Lokhnygina Y, Patel MR, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism. Circulation. 2014;130(2):138\u201346.","journal-title":"Circulation"},{"issue":"28","key":"1008_CR10","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the Aristotle trial. Eur Heart J. 2014;35(28):1864\u201372.","journal-title":"Eur Heart J"},{"issue":"6","key":"1008_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","volume":"1","author":"JH Alexander","year":"2016","unstructured":"Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, et al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine. JAMA Cardiol. 2016;1(6):673\u201381.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1008_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1111\/j.1532-5415.2006.00828.x","volume":"54","author":"MC Fang","year":"2006","unstructured":"Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"9586","key":"1008_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","volume":"370","author":"J Mant","year":"2007","unstructured":"Mant J, Hobbs FR, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the birmingham atrial fibrillation treatment of the aged study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493\u2013503.","journal-title":"Lancet"},{"issue":"13","key":"1008_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/heartjnl-2016-310358","volume":"103","author":"MN Lauw","year":"2017","unstructured":"Lauw MN, Eikelboom JW, Coppens M, Wallentin L, Yusuf S, Ezekowitz M, et al. Effects of dabigatran according to age in atrial fibrillation. Heart. 2017;103(13):1015\u201323.","journal-title":"Heart"},{"issue":"4","key":"1008_CR15","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134.","journal-title":"J Thromb Haemost"},{"key":"1008_CR16","unstructured":"R Core Team (2018) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. https:\/\/www.R-project.org. Accessed 12 Mar 2020"},{"issue":"12","key":"1008_CR17","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s00380-019-01446-6","volume":"34","author":"T Nishida","year":"2019","unstructured":"Nishida T, Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, et al. Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF registry. Heart Vessels. 2019;34(12):2021\u201330.","journal-title":"Heart Vessels"},{"key":"1008_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/VHRM.S191208","volume":"15","author":"M Monelli","year":"2019","unstructured":"Monelli M, Molteni M, Cassetti G, Bagnara L, De Grazia V, Zingale L, et al. Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study\u2014data from the registry of patients on non-vitamin K oral anticoagulants (Regina). Vasc Health Risk Manag. 2019;15:19\u201325.","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"1008_CR19","doi-asserted-by":"publisher","first-page":"e0216831","DOI":"10.1371\/journal.pone.0216831","volume":"14","author":"D Poli","year":"2019","unstructured":"Poli D, Antonucci E, Ageno W, Bert\u00f9 L, Migliaccio L, Martinese L, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: results from the prospective multicenter START2-REGISTER study. PLoS ONE. 2019;14(5):e0216831.","journal-title":"PLoS ONE"},{"key":"1008_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-01923-9","author":"V Russo","year":"2019","unstructured":"Russo V, Attena E, Di Maio M, Mazzone C, Carbone A, Parisi V, et al. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. J Thromb Thrombolysis. 2019. https:\/\/doi.org\/10.1007\/s11239-019-01923-9.","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"1008_CR21","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/jgs.15430","volume":"66","author":"CL Lai","year":"2018","unstructured":"Lai CL, Chen HM, Liao MT, Lin TT. Dabigatran, rivaroxaban, and warfarin in the oldest adults with atrial fibrillation in taiwan. J Am Geriatr Soc. 2018;66(8):1567\u201374.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1008_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bcpt.12417","volume":"117","author":"P \u0160inigoj","year":"2015","unstructured":"\u0160inigoj P, Malmstr\u00f6m RE, Vene N, R\u00f6nquist-Nii Y, Bo\u017ei\u010d-Mijovski M, Pohanka A, et al. Dabigatran concentration: variability and potential bleeding prediction in \u2018real-life\u2019 patients with atrial fibrillation. Basic Clin Pharmacol Toxicol. 2015;117(5):323\u20139.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"8","key":"1008_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00228-019-02693-2","volume":"75","author":"M Mikli\u010d","year":"2019","unstructured":"Mikli\u010d M, Mavri A, Vene N, S\u00f6derblom L, Bo\u017ei\u010d-Mijovski M, Pohanka A, et al. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation. Eur J Clin Pharmacol. 2019;75(8):1069\u201375.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1008_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.amjmed.2018.12.036","volume":"132","author":"G Patti","year":"2019","unstructured":"Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, et al. Net clinical benefit of non-vitamin K antagonist versus vitamin K antagonist anticoagulants in elderly patients with atrial fibrillation. Am J Med. 2019;132(6):749\u201357.e5.","journal-title":"Am J Med"},{"key":"1008_CR25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijcard.2019.01.071","volume":"281","author":"M Giustozzi","year":"2019","unstructured":"Giustozzi M, Vedovati MC, Verso M, Scrucca L, Conti S, Verdecchia P, et al. Patients aged 90 years or older with atrial fibrillation treated with oral anticoagulants: a multicentre observational study. Int J Cardiol. 2019;281:56\u201361.","journal-title":"Int J Cardiol"},{"issue":"1","key":"1008_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","volume":"138","author":"TF Chao","year":"2018","unstructured":"Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation. 2018;138(1):37\u201347.","journal-title":"Circulation"},{"issue":"2","key":"1008_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","volume":"131","author":"DJ Graham","year":"2015","unstructured":"Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157\u201364.","journal-title":"Circulation"},{"key":"1008_CR28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ahj.2016.01.005","volume":"175","author":"R De Caterina","year":"2016","unstructured":"De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and Other thromboembolic events in atrial fibrillation trial. Am Heart J. 2016;175:175\u201383.","journal-title":"Am Heart J"},{"issue":"9","key":"1008_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","volume":"63","author":"SG Goodman","year":"2014","unstructured":"Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events. J Am Coll Cardiol. 2014;63(9):891\u2013900.","journal-title":"J Am Coll Cardiol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01008-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-020-01008-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01008-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T00:07:49Z","timestamp":1615594069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-020-01008-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01008-1","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"10 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}